Early-stage skin cancer prognostic test developer
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Seed AMLo Biosciences, a Newcastle University spinout developing a skin cancer test, raised GBP2.45M from Future Planet Capital, Ascension and NorthStar Ventures. | $3.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.